**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Stefania Zingone Andrade Carvalho, Escola Bahiana de Medicina e Saúde Pública, Salvador - Bahia - Brazil

**Main Body of the Abstract**
Introduction: Hereditary transthyretin amyloidosis (ATTRv) is a progressive disease with a multisystem involvement. In patients with Ile107Val mutation, the clinical manifestations are sensory-motor polyneuropathy, dysautonomia, heart disease, ocular changes and involvement of cranial nerves, such as VI, IX, X and XII. Objective: Evaluate taste sensitivity in individuals with ATTRv amyloidosis, with Ile107Val mutation. Method: Observational, descriptive and cross-sectional study, with a convenience sample. A taste sensitivity test was used to evaluate the four primary flavors (sweet; salty; sour; bitter), in symptomatic patients of a specialized care service for patients with amyloidosis in Brazil, between July 2021 to July 2022. Results: All participants (N = 11) presented dysgeusia for all solutions, regardless of their concentration. In 09 participants there was ageusia for the lowest concentrations, especially for the sweet taste. Discussion: There is a heterogeneity of symptoms with cranial nerves involvement associated with different types of amyloidosis in the literature, however such findings are still insufficient. Amyloid infiltrates in peripheral nerves causing polyneuropathy in ATTRv have already been described, as well as tongue atrophy and fasciculation in Ile107Val. To date, there is only one case report with severe dysgeusia and metallic taste sensation in a patient with Ile107Val, similar to the present study. Further investigations are needed to confirm these results. Conclusion: These are preliminary results that describe the presence of dysgeusia in this population, associated with clinical findings of cranial nerves involvement.



Taste sensitivity evaluation in patients with hereditary amyloidosis associated with transthyretin (TTR) Ile107Val, in Brazil: a preliminary study PB80 (#390)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.